Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — 39th Annual J.P. Morgan Healthcare Conference 2021
35 slides from Anaptysbio's conference presentation, Jan 11, 2021
Slide 1: Corporate Overview
AnaptysBioW Corporate Overview 39th Annual J.P. Morgan Healthcare Conference January 11-14! 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement VV This presentation and any accompanying oral presentation contain “forward-looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our
Slide 3: AnaptysBio: Clinical-Stage Novel Antibody R&D Engine
AnaptysBio: Clinical-Stage Novel Antibody R&D Engine Vv Advancing First-In-Class Immunology Therapeutics to Patients Wholly-Owned Multiple imsidolimab Phase 2 readouts anticipated in 2021, in addition to Clinical Catalysts advancement of imsidolimab into Phase 3 GPP registration trial 8 immuno-derma
Slide 4: Wholly-Owned Product Pipeline
Wholly-Owned Product Pipeline VY 8 immuno-dermatology indications under Phase 2/3 development during 2021 Antibody Therapeutic Development Stage & Anticipated Milestones Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Generalized GALLOP: Phase 2 Data To Be Presented At 2021 Medical
Slide 5: Partnered Product Pipeline
Partnered Product Pipeline \W Anticipate Royalties On Dostarlimab and Zejula™ Starting 2021 ; Tecra Development Stage & Anticipated Milestones exw Antibody Progr ropes ame am Indication Discovery _Precinical Phase 1 Phase 2 Phase 3 Rights Dostarlimab . BLA Acceptance sntsPD-1 Aragon ores MOONSTONE 8
Slide 6: Anticipated Wholly-Owned Clinical Catalysts
Anticipated Wholly-Owned Clinical Catalysts Vv Program Clinical Catalyst Timing GALLOP: GPP Phase 2 Trial GPP Phase 3 Trial POPLAR: PPP Phase 2 Trial Imsidolimab (ANBO19, anti-IL-36R) EMERGE: EGFRi/MEKi Mediated Skin Toxicity Phase 2 Trial INSPIRE: Ichthyosis Phase 2 Trial HARP: Hidradenitis Suppura
Slide 7: Wholly-Owned Pipeline: Imsidolimab (ANB019, Anti-IL-36R)
AnaptysBioW Wholly-Owned Pipeline: Imsidolimab (ANB019, Anti-IL-36R) Generalized Pustular Psoriasis Palmoplantar Pustulosis EGFRi-Mediated Skin Toxicity ichthyosis Hidradenitis Suppurativa Acne
Slide 8: IL-36 Dysfunction Mediates Severe Inflammatory Disease
IL-36 Dysfunction Mediates Severe Inflammatory Disease Y Genetic Association with Generalized Pustular Psoriasis ivi Disease Patients i Normal Individuals ‘Gitciiodied sionalia cuss ayesancasial Treated Patients IL-36 receptor antagonist or elevated IL-36 cytokine levels IL-36 cytokine signaling bal
Slide 9: Generalized Pustular Psoriasis (GPP)
Generalized Pustular Psoriasis (GPP) Orphan Disease Associated with IL-36 Receptor Antagonist Mutations GPP is a systemic, life-threatening inflammatory disease characterized by widespread pustules - Patients have a high fever and elevated levels of serum CRP and inflammatory cytokines (e.g. IL-8) S
Slide 10: GALLOP: Imsidolimab Moderate-to-Severe GPP Phase 2 Trial
GALLOP: Imsidolimab Moderate-to-Severe GPP Phase 2 Trial Vv Trial Design Treatment Period Monitoring Period . 2g ge zs 32 3! oS de ag 5 = & = Imsidolimab 750mg IV Loading Dose & + 100mg SC q4w Maintenance Dose Ht ae Patient + Moderate-to-severe adult generalized pustular psoriasis patients Populatio
Slide 11: GALLOP: Interim Analysis Data
GALLOP: re Mies 2 Interim Analysis Data ficacy With Imsidolimab Monothe ising Eft itiation in Mid-2021 A Anticipate + Rapid and promising efficacy - 60f8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29 — Rapid reduction of skin pustules by 60
Slide 12: Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis (PPP) Orphan Disease Associated With Elevated IL-36 Cytokine Levels Severe inflammation of hands and feet Significant pain and inability to stand, walk or work No approved therapeutic options in this indication PPP is an orphan disease that affects approximately 150,000 patie
Slide 13: POPLAR: Imsidolimab Palmoplantar Pustulosis Phase 2 Trial
POPLAR: Imsidolimab Palmoplantar Pustulosis Phase 2 Trial Y Top-Line Data Anticipated Q1 2021 Treatment Period Monitoring Period i i i Imsidolimab 200mg SC Loading Dose + | 100mg SC q4w Maintenance Dose Placebo =} Patient . Adult Moderate-to-Severe Palmoplantar Pustulosis Population Key Endpoints PP
Slide 14: EGFR/MEK inhibitor papulopustular rash
Papulopustular rash is the most frequent clinically significant dermatological toxicity associated with EGFR/MEK inhibitor solid tumor treatment Majority of patients experience dose-limiting skin toxicity and/or discontinuation of EGFR/MEK inhibitor therapy Recent human translational data indicates
Slide 15: EMERGE: Imsidolimab EGFRi/MEKi-Mediated Skin Tox Phase 2 Trial
EMERGE: Imsidolimab EGFRi/MEKi-Mediated Skin Tox Phase 2 Trial Y Interim Top-Line Data Anticipated End 2021 Treatment Period Monitoring Period i i i Imsidolimab 400mg SC Loading Dose + | 200mg SC q4w Maintenance Dose Placebo |—Se gee gee ity pyle + Adult patients undergoing cancer therapy with oral
Slide 16: New Indication: Ichthyosis
New Indication: Ichthyosis Orphan Disease Associated With Excess IL-36 Signaling + Ichthyosis is a rare, orphan dermatological indication with high medical unmet need + Patients suffer from dry, scaly skin, often leading to itch and painful cracking * Translational studies have demonstrated high IL-
Slide 17: INSPIRE: Imsidolimab Ichthyosis Phase 2 Trial
INSPIRE: Imsidolimab Ichthyosis Phase 2 Trial Interim Top-Line Data Anticipated in 2022 Treatment Period Open-Label Period 3 bef 2 = 2 2 Imsidolimab 400mg SC Loading Dose + 200mg SC q4w Maintenance Dose Alll Patients Receive 200mg SC qaw ‘Maintenance Dose Placebo Pia ee see Patient + Patients diagno
Slide 18: New Indication: Hidradenitis Suppurativa
New Indication: Hidradenitis Suppurativa Vv IL-36 Cytokine Over-Expression Observed in Patient Skin Biopsies * Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease - Painful nodules present in intertriginous areas that progress to abscesses, sinus tracks and scarring * Current treatm
Slide 19: New Indication: Moderate-to-Severe Acne
New Indication: Moderate-to-Severe Acne Large Market Opportunity Associated with IL-36 Signaling + Acne is the most common skin disorder in the United States, with approximately 7 million patients diagnosed with moderate-to-severe disease + Believed to be driven by immune response to P. acnes, resul
Slide 20: Wholly-Owned Pipeline: ANB030 and ANB032 Inflammatory Diseases
AnaptysBioW Wholly-Owned Pipeline: Anti-PD-1 Agonist (ANB030) Anti-BTLA Modulator (ANB032) Inflammatory Diseases
Slide 21: Anti-Inflammatory Checkpoint Receptor Antibodies
Anti-Inflammatory Checkpoint Receptor Antibodies Novel Therapeutic Class Validated By Human Genetics Anti-inflammatory checkpoint receptor antibodies have unique binding properties that are challenging to generate using traditional antibody technologies AnaptysBio’s technology platform has successfu
Slide 22: ANB030: PD-1 Agonist Antibody
ANBO30: PD-1 Agonist Antibody Vv Novel Anti-Inflammatory Mechanism Applicable to T-Cell Driven Inflammatory Conditions Activated T Cell Antigen Presenting Cell * PD-1 is a key inhibitory immune checkpoint receptor responsible for down-regulating T- cell mediated immune responses i H Healthy * Insuff
Slide 23: ANB032: BTLA Modulator Antibody
Emerging Lymphoid and Myeloid Immune Control Mechanism Broadly Applicable to Inflammatory Disease ANBO032: BTLA Modulator Antibody ¥ * BTLAis an inhibitory checkpoint receptor A ANB032 responsible for regulating activation of lymphoid (T and B) cells and myeloid (dendritic) cells ° Genetic defects i
Slide 24: Wholly-Owned Pipeline: Etokimab (ANB020, Anti-IL-33)
AnaptysBioW Wholly-Owned Pipeline: Etokimab (ANBO020, Anti-IL-33) Chronic Rhinosinusitis with Nasal Polyps
Slide 25: ECLIPSE: Etokimab CRSwNP Phase 2 Trial
ECLIPSE: Etokimab CRSwWNP Phase 2 Trial Vv Discontinue further development of etokimab Treatment Period Monitoring Period Week 16 i Etokimab 300mg SC Loading Dose + | f 150mg SC q8w Maintenance Dose + MFNS Placebo + MENS —————— Sea MFNS = see = mometasone furoate nasal spray geet < Patient Adult Chr
Slide 26: ECLIPSE: Etokimab CRSwNP Phase 2 Trial Results
ECLIPSE: Etokimab CRSwNP Phase 2 Trial Discontinue further development of etokimab 7 - End Paramet + Etokimab q4w and q8w treatment arms failed pares cermin! to achieve NPS and SNOT-22 statistical significance over placebo at the Week 16 final Baseline: ae a aa analysis Week 16 16% 17% 1% - Both arm
Slide 27: Partnered Pipeline: GSK Immuno-Oncology Collaboration
AnaptysBioW Partnered Pipeline: GSK Immuno-Oncology Collaboration Dostarlimab (GSK4057190, anti-PD-1 Antagonist) Cobolimab (GSK4069889, anti-TIM-3 Antagonist) TSR-033 (GSK4074386, anti-LAG-3 Antagonist)
Slide 28: Dostarlimab US and EU Approval Anticipated in H1 2021
Dostarlimab US and EU Approval Anticipated in H1 2021 GSK Immuno-Oncology Collaboration VY Anticipate Royalties From Sales of Dostarlimab and Zejula™ in 2021 BLA and MAA Accepted Giaradomeur US and EU Approval Anticipated H1 2024 GARNET (n=125) RUBY (n=470) dMMR Pan-Tumor BLA Acceptance Anticipated
Slide 29: Proprietary Technology Platform
AnaptysBioW Proprietary Technology Platform
Slide 30: Somatic Hypermutation (SHM) Platform
Somatic Hypermutation (SHM) Platform Y Proprietary Platform Incorporates in vitro SHM and Iterative Antibody Evolution In Vitro SHM Iterative Antibody Evolution Starting Library AIpunauced Selection —_—> Selection +¥ tH 4¥ \ Optimized AID-Induced . ‘Antibody SHM In vitro SHM permits access to biolog
Slide 31: Somatic Hypermutation (SHM) Platform: Advantages
Somatic Hypermutation (SHM) Platform VY Advantages Over Competing Antibody Technologies Unprecedented antibody diversity through SHM — In situ antibody diversity generation outside of the constraints of an in vivo environment High potency & functional activity — Only small doses may be required to c
Slide 32: Summary
AnaptysBioW Summary
Slide 33: Anticipated Wholly-Owned Clinical Catalysts
Anticipated Wholly-Owned Clinical Catalysts VY Program Clinical Catalyst Timing GALLOP: GPP Phase 2 Trial GPP Phase 3 Trial POPLAR: PPP Phase 2 Trial Imsidolimab (ANBO19, anti-IL-36R) EMERGE: EGFRi/MEKi Mediated Skin Toxicity Phase 2 Trial INSPIRE: Ichthyosis Phase 2 Trial HARP: Hidradenitis Suppura
Slide 34: AnaptysBio: Clinical-Stage Novel Antibody R&D Engine
AnaptysBio: Clinical-Stage Novel Antibody R&D Engine Vv Advancing First-In-Class Immunology Therapeutics to Patients Wholly-Owned Multiple imsidolimab Phase 2 readouts anticipated in 2021, in addition to Clinical Catalysts advancement of imsidolimab into Phase 3 GPP registration trial 8 immuno-derma
Slide 35: AnaptysBioW
AnaptysBioW
Anaptysbio — 39th Annual J.P. Morgan Healthcare Conference 2021 on 6ix